Trial reportEuropean journal of clinical pharmacology1991
Coronary drug project: experience with niacin. Coronary Drug Project Research Group.
Trial report in European journal of clinical pharmacology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000483. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Coronary Drug Project Mortality Surveillance
Open the trial in the graphWho cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Niacin for primary and secondary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2017 · on this mapPooled it
- Statins and fibrates for preventing melanoma.The Cochrane database of systematic reviews · 2005Pooled it
- Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.Vascular health and risk management · 2015Trial
- Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.Vascular health and risk management · 2012Trial
- Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.American heart journal · 2009Trial
- Review
- Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction.Journal of the American Heart Association · 2025Review
- Niacin and Stroke: The Role of Supplementation and Emerging Concepts in Clinical Practice, a Narrative Review.Current issues in molecular biology · 2025Review
- NAD metabolism and heart failure: Mechanisms and therapeutic potentials.Journal of molecular and cellular cardiology · 2024Review
- Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns.Endocrine reviews · 2023Review
- Review
- The effects of nicotinamide adenine dinucleotide in cardiovascular diseases: Molecular mechanisms, roles and therapeutic potential.Genes & diseases · 2022Review
- NADEMBO molecular medicine · 2021Review
- NADFrontiers in physiology · 2020Review
- Niacin: an old lipid drug in a new NADJournal of lipid research · 2019Article
- Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies.Current cardiology reviews · 2018Review
- Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.Molecular aspects of medicine · 2013Review
- Intolerance to statins: mechanisms and management.Diabetes care · 2013Review
- Niacin added to statins for cardiovascular disease.Canadian family physician Medecin de famille canadien · 2012Article
- Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice.Journal of cardiovascular pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Niacin was one of the treatments compared in the Coronary Drug Project, a placebo-controlled, multicenter trial of lipid-lowering drugs in the secondary prevention of coronary heart disease. A total of 1119 men, aged 30-64 at entry, were randomized to niacin and 2789 to placebo by the end of recruitment in March 1969. Although side-effects interfered with adherence to the niacin regimen, it was the most effective agent in achieving cholesterol-lowering (10% overall); other agents in the trial were clofibrate, dextrothyroxine, and conjugated equine estrogens. At the scheduled conclusion of the trial in February 1975, the niacin-treated group exhibited a statistically significantly lower incidence of definite, non-fatal myocardial infarction (MI) than the placebo group. There was a trend toward improvement in the life-table mortality curve, but this was not statistically significant. In 1981 an extended follow-up was carried out concerning vital status for the 6008 men who were still alive at the end of treatment and active follow-up in the trial in 1975 (827 in the niacin group and 2008 in placebo groups). Vital status was determined for 99.1% of these men after a mean of 9 years from conclusion of the trial. In the group previously randomized to niacin, there were 69 (11%) fewer deaths than were expected on the basis of mortality in the placebo group. This difference was significant (z = -3.52; P = 0.0004). The data also suggested that patients with a higher baseline cholesterol experienced greater benefit from niacin therapy, as did those with the best response to the drug.(ABSTRACT TRUNCATED AT 250 WORDS)
Indexed as
Identifiers
2044644W68098806What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.